Analysis | Metabolite Name | Measured Value | Units | CASE_CONTROL | Chemotherapy | Drug | Race | TIMEPOINT | Tamoxyfen | Taxane |
---|---|---|---|---|---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | 1116 | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | 1225 | Peak area | Case | Y | Exemestane | White | Baseline | N | Y |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | 1477 | Peak area | Control | Y | Exemestane | White | Baseline | N | Y |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | 1513 | Peak area | Control | Y | Exemestane | White | 3 Month | N | N |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | 1857 | Peak area | Control | N | Letrozole | White | Baseline | Y | N |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | 1862 | Peak area | Case | N | Letrozole | Black | 3 Month | N | N |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | 1945 | Peak area | Control | N | Exemestane | White | 3 Month | N | N |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | 2422 | Peak area | Control | N | Letrozole | Black | 3 Month | N | N |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | 3979 | Peak area | Control | N | Letrozole | White | 3 Month | Y | N |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | 4735 | Peak area | Control | Y | Exemestane | White | 3 Month | Y | Y |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | N | Exemestane | Black | 3 Month | N | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | N | Exemestane | Black | Baseline | N | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | N | Exemestane | White | 3 Month | N | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | N | Exemestane | White | 3 Month | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | N | Exemestane | White | Baseline | N | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | N | Exemestane | White | Baseline | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | N | Letrozole | Black | Baseline | N | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | N | Letrozole | White | 3 Month | N | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | N | Letrozole | White | 3 Month | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | N | Letrozole | White | Baseline | N | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | N | Letrozole | White | Baseline | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | Y | Exemestane | Black | 3 Month | N | Y | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | Y | Exemestane | Black | Baseline | N | Y | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | Y | Exemestane | White | 3 Month | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | Y | Exemestane | White | 3 Month | Y | Y | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | Y | Exemestane | White | Baseline | N | Y | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | Y | Exemestane | White | Baseline | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | Y | Exemestane | White | Baseline | Y | Y | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | Y | Letrozole | White | 3 Month | Y | Y | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Case | Y | Letrozole | White | Baseline | Y | Y | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | N | Exemestane | Black | 3 Month | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | N | Exemestane | Black | Baseline | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | N | Exemestane | White | 3 Month | N | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | N | Exemestane | White | 3 Month | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | N | Exemestane | White | Baseline | N | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | N | Exemestane | White | Baseline | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | N | Letrozole | Black | Baseline | N | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | N | Letrozole | White | 3 Month | N | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | N | Letrozole | White | 3 Month | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | N | Letrozole | White | Baseline | N | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | N | Letrozole | White | Baseline | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | Y | Exemestane | White | 3 Month | N | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | Y | Exemestane | White | 3 Month | N | Y | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | Y | Exemestane | White | 3 Month | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | Y | Exemestane | White | Baseline | N | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | Y | Exemestane | White | Baseline | N | Y | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | Y | Exemestane | White | Baseline | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | Y | Exemestane | White | Baseline | Y | Y | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | Y | Letrozole | White | 3 Month | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | Y | Letrozole | White | 3 Month | Y | Y | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | Y | Letrozole | White | Baseline | Y | N | |
Reversed phase NEGATIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M-H)- | Peak area | Control | Y | Letrozole | White | Baseline | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | 2566 | Peak area | Control | N | Exemestane | Black | 3 Month | Y | N |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | N | Exemestane | Black | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | N | Exemestane | Black | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | N | Exemestane | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | N | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | N | Exemestane | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | N | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | N | Letrozole | Black | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | N | Letrozole | Black | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | N | Letrozole | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | N | Letrozole | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | N | Letrozole | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | N | Letrozole | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | Y | Exemestane | Black | 3 Month | N | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | Y | Exemestane | Black | Baseline | N | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | Y | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | Y | Exemestane | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | Y | Exemestane | White | Baseline | N | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | Y | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | Y | Exemestane | White | Baseline | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | Y | Letrozole | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Case | Y | Letrozole | White | Baseline | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | N | Exemestane | Black | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | N | Exemestane | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | N | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | N | Exemestane | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | N | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | N | Letrozole | Black | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | N | Letrozole | Black | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | N | Letrozole | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | N | Letrozole | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | N | Letrozole | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | N | Letrozole | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | Y | Exemestane | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | Y | Exemestane | White | 3 Month | N | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | Y | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | Y | Exemestane | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | Y | Exemestane | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | Y | Exemestane | White | Baseline | N | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | Y | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | Y | Exemestane | White | Baseline | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | Y | Letrozole | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | Y | Letrozole | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | Y | Letrozole | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+H)+[-H2O] | Peak area | Control | Y | Letrozole | White | Baseline | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 1291 | Peak area | Case | N | Exemestane | White | Baseline | N | N |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 1363 | Peak area | Case | Y | Exemestane | Black | Baseline | N | Y |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 1366 | Peak area | Control | Y | Exemestane | White | 3 Month | Y | N |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 1684 | Peak area | Control | Y | Letrozole | White | 3 Month | Y | Y |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 1855 | Peak area | Control | N | Letrozole | White | Baseline | N | N |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 2034 | Peak area | Control | N | Exemestane | White | 3 Month | N | N |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 2145 | Peak area | Control | Y | Exemestane | White | Baseline | N | Y |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 2271 | Peak area | Control | Y | Exemestane | White | 3 Month | N | Y |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 2322 | Peak area | Control | N | Exemestane | White | 3 Month | N | N |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 2428 | Peak area | Control | N | Exemestane | White | Baseline | N | N |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 2571 | Peak area | Case | N | Exemestane | White | 3 Month | Y | N |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 2798 | Peak area | Case | N | Letrozole | White | Baseline | N | N |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 3168 | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 3294 | Peak area | Case | N | Letrozole | White | Baseline | Y | N |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 3445 | Peak area | Case | Y | Exemestane | White | Baseline | N | Y |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 3486 | Peak area | Case | Y | Letrozole | White | Baseline | Y | Y |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 3527 | Peak area | Control | N | Letrozole | White | 3 Month | N | N |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 3813 | Peak area | Case | N | Letrozole | White | 3 Month | Y | N |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 4014 | Peak area | Control | N | Exemestane | Black | 3 Month | Y | N |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 4503 | Peak area | Control | N | Exemestane | White | 3 Month | N | N |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | 4702 | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | N | Exemestane | Black | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | N | Exemestane | Black | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | N | Exemestane | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | N | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | N | Exemestane | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | N | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | N | Letrozole | Black | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | N | Letrozole | Black | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | N | Letrozole | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | N | Letrozole | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | N | Letrozole | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | N | Letrozole | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | Y | Exemestane | Black | 3 Month | N | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | Y | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | Y | Exemestane | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | Y | Exemestane | White | Baseline | N | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | Y | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | Y | Exemestane | White | Baseline | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | Y | Letrozole | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Case | Y | Letrozole | White | Baseline | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | N | Exemestane | Black | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | N | Exemestane | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | N | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | N | Exemestane | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | N | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | N | Letrozole | Black | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | N | Letrozole | Black | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | N | Letrozole | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | N | Letrozole | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | N | Letrozole | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | N | Letrozole | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | Y | Exemestane | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | Y | Exemestane | White | 3 Month | N | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | Y | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | Y | Exemestane | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | Y | Exemestane | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | Y | Exemestane | White | Baseline | N | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | Y | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | Y | Exemestane | White | Baseline | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | Y | Letrozole | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | Y | Letrozole | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | Y | Letrozole | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | N-ACETYL-L-ASPARTIC ACID (CAS# 997-55-7); (M+NA)+ | Peak area | Control | Y | Letrozole | White | Baseline | Y | Y |